Loading
Led MEDALIST and COMMANDS, which made luspatercept a first-line treatment for anaemia in lower-risk MDS.
Uwe Platzbecker (Leipzig) was a principal investigator of MEDALIST and led COMMANDS, the trials establishing luspatercept for transfusion-dependent anaemia in lower-risk myelodysplastic syndromes, first after and then instead of erythropoiesis-stimulating agents. He coordinates the German MDS Study Group and the European MDS registry and has led trials of hypomethylating agent combinations in higher-risk disease.
Shares COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions, Myelodysplastic syndromes / neoplasms (MDS) and the tags mds, trialist.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag mds.
Shares Acute myeloid leukaemia and the tag trialist.
Shares Acute myeloid leukaemia and the tag trialist.
Shares Acute myeloid leukaemia and the tag trialist.
Shares IMerge, COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions, Myelodysplastic syndromes / neoplasms (MDS).
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.